Image via Wikipedia
It has been about 8 years since Salsabil, the first Palestinia baby suffering congenital immunodeficiency (Ada-Scid), has been healed using gene therapy. And it has been about 7 years since her story to Abdul Rahim’s one, a Pakistani baby born in the end of 2006 in Qatar.
His parents did lose 3 children because of Ada-Scid, and Abdul’s case is one of the most symbolic.
Just after his birth doctors did diagnose his illness and succeeded to healt his pneumonia during his first days of life.
So Abdul’s parents and doctors who were follow him contacted the San Raffaele Telethon
Academic institutions are in a much better position than pharmaceutical companies to make the best decisions about which therapies deserve further development. That was the underlying message from a pair of Stanford researchers at a panel on stem cell science at last weekend’s Association of Health Care Journalism 2015 conference.
“There’s an inherent flaw in our system,” said Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. “Companies are driven by the desire for profits rather than the desire to find the best therapy, and they often give up on discoveries too early.”
Image by pianetatschai via Flickr
It was stunning to see them closed inside of those plastic bubbles, kept far from all external contact because their immune system does not react against any foreign antigens. Today scientists can say that ADA-SCID (adenosine deaminase deficiency), a serious combined immunodeficiency caused due to a lack of the adenosine deaminase enzyme, has been definitively defeated by gene therapy developed at San Raffaele of Milan.
The final study, which combined the conclusions of clinical studies, which began in 2000 on strategic therapies developed by the HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy) group,
About five years ago, Professor Janet Sawicki at the Lankenau Institute in Pennsylvania read an article about nanoparticles developed by MIT’s Daniel Anderson and Robert Langer for gene therapy, the insertion of genes into living cells for the treatment of disease. Sawicki was working on treating ovarian cancer by delivering — through viruses — the gene for the diphtheria toxin, which kills tumor cells (…)
Gregg Semenza, M.D., Ph.D.
Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers at Johns Hopkins have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation. The findings, published online last week in the early edition of the Proceedings of the National Academy of Sciences, hold promise for developing clinical therapies.
“In a young, healthy individual, hypoxia